MX2010003630A - Administracion sostenida de analogos de compstatina desde geles. - Google Patents

Administracion sostenida de analogos de compstatina desde geles.

Info

Publication number
MX2010003630A
MX2010003630A MX2010003630A MX2010003630A MX2010003630A MX 2010003630 A MX2010003630 A MX 2010003630A MX 2010003630 A MX2010003630 A MX 2010003630A MX 2010003630 A MX2010003630 A MX 2010003630A MX 2010003630 A MX2010003630 A MX 2010003630A
Authority
MX
Mexico
Prior art keywords
sustained delivery
gels
compstatin analogs
compstatin analog
compstatin
Prior art date
Application number
MX2010003630A
Other languages
English (en)
Spanish (es)
Inventor
Pascal Deschatelets
Paul Olson
Cedric Francois
Original Assignee
Potentia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Potentia Pharmaceuticals Inc filed Critical Potentia Pharmaceuticals Inc
Publication of MX2010003630A publication Critical patent/MX2010003630A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2010003630A 2007-10-02 2008-10-02 Administracion sostenida de analogos de compstatina desde geles. MX2010003630A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97691907P 2007-10-02 2007-10-02
US2646008P 2008-02-05 2008-02-05
PCT/US2008/078593 WO2009046198A2 (en) 2007-10-02 2008-10-02 Sustained delivery of compstatin analogs from gels

Publications (1)

Publication Number Publication Date
MX2010003630A true MX2010003630A (es) 2010-04-21

Family

ID=40526950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003630A MX2010003630A (es) 2007-10-02 2008-10-02 Administracion sostenida de analogos de compstatina desde geles.

Country Status (12)

Country Link
US (1) US20110182877A1 (enExample)
EP (1) EP2207530A4 (enExample)
JP (1) JP2010540654A (enExample)
KR (2) KR20150080007A (enExample)
CN (1) CN101854916A (enExample)
AU (1) AU2008308657A1 (enExample)
BR (1) BRPI0817524A2 (enExample)
CA (1) CA2701470A1 (enExample)
MX (1) MX2010003630A (enExample)
RU (1) RU2505311C2 (enExample)
WO (1) WO2009046198A2 (enExample)
ZA (1) ZA201002365B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US20110092446A1 (en) * 2007-07-20 2011-04-21 Cedric Francois Compositions and methods for treatment of trauma
WO2009121065A2 (en) * 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
TWI492769B (zh) * 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
DK2425814T3 (da) 2010-09-03 2013-09-08 Novagali Pharma Sa Vand-i-olieemulsion til behandling af en øjensygdom
US9107822B2 (en) 2010-09-03 2015-08-18 Santen Sas Water-in oil type emulsion for treating a disease of the eye
EA028375B1 (ru) 2010-09-03 2017-11-30 Сантен Сас Композиция в виде эмульсии типа "вода-в-масле" для интраокулярного введения
CA2835627C (en) 2011-05-11 2023-01-10 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
EP2723361B1 (en) * 2011-06-22 2019-10-30 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
WO2014028861A1 (en) 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
EP3929206A1 (en) 2012-11-15 2021-12-29 Apellis Pharmaceuticals, Inc. Long-acting compstatin analogs and related compositions and methods
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9940683B2 (en) 2013-07-31 2018-04-10 Elwha Llc Managing a risk of a liability that is incurred if a subject treated for a condition is retreated within a specified time period
US20150039337A1 (en) * 2013-07-31 2015-02-05 Elwha Llc Managing a risk of a liability that is incurred if one or more subjects each treated for a respective condition are retreated within a respective specified time period
EP2918262B1 (en) 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
HUE045646T2 (hu) 2014-06-12 2020-01-28 Ra Pharmaceuticals Inc Komplement aktivitás modulálása
CA2970502A1 (en) * 2014-12-12 2016-06-16 The Schepens Eye Research Institute, Inc. Gdnf induction for the treatment of retinal disorders
WO2016123371A1 (en) 2015-01-28 2016-08-04 Ra Pharmaceuticals, Inc. Modulators of complement activity
EP3095440B1 (en) 2015-05-19 2020-01-15 PLS-Design GmbH Antigen-specific immunotherapy using tolerizing liposomes
CA3287719A1 (en) * 2015-10-07 2026-03-02 Apellis Pharmaceuticals, Inc. Use of long-acting compstatin analog for treating a complement-mediated disorder
EP4218790B1 (en) * 2015-12-16 2026-02-18 UCB Holdings, Inc. Modulators of complement activity
CA3045114A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
CN116059313A (zh) 2017-04-07 2023-05-05 阿佩利斯制药有限公司 给药方案以及相关组合物和方法
KR20240167712A (ko) 2017-12-15 2024-11-27 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
US12558398B2 (en) 2019-06-04 2026-02-24 Ucb Holdings, Inc. Inflammatory disease treatment with complement inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DK1549333T3 (da) * 2002-09-20 2012-01-16 Univ Pennsylvania Compstatinanaloge med forbedret aktivitet
CA2625206C (en) * 2005-10-08 2021-12-07 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
CN106188239B (zh) * 2005-11-28 2020-01-07 宾夕法尼亚州大学理事会 有效的坎普他汀类似物
KR20080087814A (ko) * 2005-12-22 2008-10-01 알콘 리서치, 리미티드 보체 인자 ｈ의 위험 변이체가 있는 환자에서 연령 관련황반변성의 예방 및 치료를 위한 ｃ3-전환효소 저해제
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
AU2008214359B2 (en) * 2007-02-05 2014-01-16 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders

Also Published As

Publication number Publication date
RU2010113513A (ru) 2011-11-10
KR20100094453A (ko) 2010-08-26
EP2207530A4 (en) 2013-09-11
CN101854916A (zh) 2010-10-06
KR20150080007A (ko) 2015-07-08
WO2009046198A3 (en) 2009-07-16
WO2009046198A2 (en) 2009-04-09
JP2010540654A (ja) 2010-12-24
RU2505311C2 (ru) 2014-01-27
BRPI0817524A2 (pt) 2017-05-02
US20110182877A1 (en) 2011-07-28
EP2207530A2 (en) 2010-07-21
ZA201002365B (en) 2010-12-29
AU2008308657A1 (en) 2009-04-09
CA2701470A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
WO2009046198A3 (en) Sustained delivery of compstatin analogs from gels
Zhang et al. Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates
GB2471304B (en) A pre-filled syringe or autoinjector
WO2012054500A3 (en) Compositions for drug administration
PH12013500741A1 (en) Peptide-based in vivo sirna delivery system
MX2012006998A (es) Composicion antitranspirante/desodorante anhidra liquida.
EP4403197A3 (en) Injectable formulations for organ augmentation
MX2014007233A (es) Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
MX2010005272A (es) Dispensador de gel dosificado.
WO2007085629A3 (en) Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents
EA201270167A1 (ru) Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения
PH12015500850A1 (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
PE20121517A1 (es) Compuestos lipopeptidos y metodos relacionados
TN2012000261A1 (en) Aerosol formulation for copd
MX2014002062A (es) Nanoparticulas de peptido y usos de las mismas.
PE20130379A1 (es) Metodos para el tratamiento de las ulceras del pie diabetico
AR074046A1 (es) Envase para la administracion iontoforetica de un farmaco
ZA200807027B (en) Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
EA201591188A1 (ru) Доставка глатирамера ацетата через слизистую оболочку
AR081875A1 (es) Utilizacion de la asociacion de un inhibidor de la corriente sinusal iy de un inhibidor de la enzima de conversion de la angiotensina para el tratamiento de la insuficiencia cardiaca
MX365599B (es) Moleculas de transporte especificas de proteoglicano c4s.
WO2011064316A3 (en) Mucosal delivery compositions comprising a peptide complexed with a crown comppound and/or a counter ion
EP1758923B8 (en) Peptide substance restoring myocardium function
MX2010001429A (es) Mendicamento en polvo para distribucion nasal de ácido ascórbico para reducir la toxicidad inducida por apomorfina hacia rejido ciliaco.
SA112340077B1 (ar) نظام إيصال siRNA داخل الكائن الحي يعتمد على الببتيدات